Journal
BMC MEDICINE
Volume 19, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12916-021-02006-4
Keywords
Tumor infiltration lymphocyte; Cancer treatment; Immunotherapy; Gene editing; Clinical trials
Categories
Funding
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Platform Improvement of Clinical Trial Capability) [2020-I2M-2-007]
- Chinese Academy of Medical Sciences [2019XK320068]
- Beijing Municipal Science and Technology Commission (International Pharmaceutical Clinical Research and Development Platform 2015)
- non-profit central research Institute fund of Chinese academy of medical sciences [2019PT3200003]
Ask authors/readers for more resources
TIL therapy involves harvesting, culturing, and infusing infiltrated lymphocytes from tumors, offering unique advantages in treating solid tumors, yet facing limitations in its current applications.
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior tumor-homing ability, and low off-target toxicity endow TIL therapy unique advantages in treating solid tumors compared with other adoptive cellular therapies. Nevertheless, the successful application of TIL therapy currently is still limited to several types of tumors. Herein in this review, we summarize the fundamental work in the field of TIL therapy and the current landscape and advances of TIL clinical trials worldwide. Moreover, the limitations of the current TIL regimen have been discussed and the opportunities and challenges in the development of next-generation TIL are highlighted. Finally, the future directions of TIL therapy towards a broader clinical application have been proposed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
